Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...

VX-880 (formerly known as STx-02) derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form ...

Hero Pleasure Plus VX is the mid variant in the Pleasure Plus lineup and is priced at Rs. 75,213 (ex-showroom, Delhi). This VX variant comes with an engine putting out and of max power and max ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $123.2 billion, finds itself at a critical juncture as it navigates ...

2-Year U.S. Treasury Note Continuous Contract $103.395-0.109-0.11% 5-Year U.S. Treasury Note Continuous Contract $107.539-0.281-0.26% 10-Year U.S. Treasury Note Continuous Contract $110.469-0.406 ...

AlgoTx’s mid-stage stumble on Tuesday comes after Vertex earlier this month won the FDA’s approval for Journavx, an inhibitor of the NaV1.8 voltage-gated sodium channel that marks the first new ...